<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04651946</url>
  </required_header>
  <id_info>
    <org_study_id>EOC-METHY</org_study_id>
    <nct_id>NCT04651946</nct_id>
  </id_info>
  <brief_title>Cell-free DNA Methylation for Epithelial Ovarian Cancer</brief_title>
  <official_title>Cell-free DNA Methylation for the Diagnosis and Monitoring of Epithelial Ovarian Cancer: The Training and Validation Sets in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lei Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liquid biopsy is challenging for the diagnosis of epithelial ovarian cancer (EOC). In this&#xD;
      study, we performed the methylation testing of host DNA, namely, OPCML, FODX3 and CDH13, in&#xD;
      the peripheral serum to discover the diagnostic and supervision roles of DNA methylation in&#xD;
      EOC patients. The study compromises two stages.&#xD;
&#xD;
      In the training set, DNA methylation testing is performed in the ovarian tissues from EOC and&#xD;
      paired benign ovarian tumor patients. The cut-off values of methylation are produced in this&#xD;
      stage. On the meantime, serum DNA methylation testing is also performed to reveal its&#xD;
      accordance and accuracy compared with the results of ovarian tissues.&#xD;
&#xD;
      In the validation set, serum DNA methylation testing is performed in unselected ovarian tumor&#xD;
      patients with definite cut-off values to validate its accuracy based on known histology of&#xD;
      ovarian tumors.&#xD;
&#xD;
      In training and validation sets, serum DNA methylation is also performed after major&#xD;
      surgeries for EOC as to illustrate the changes of methylation testing, therefore, reflection&#xD;
      the supervision role of DNA methylation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2020</start_date>
  <completion_date type="Anticipated">November 26, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 26, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All eligible patients accept DNA methylation testing in serum and in ovarian tissues.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cut-off values of targeted DNA methylation in epithelial ovarian cancer</measure>
    <time_frame>Two years</time_frame>
    <description>The cut-off values are achieve by paired epithelial ovarian cancer and benign ovarian tumor patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Accuracy of serum DNA methylation in epithelial ovarian cancer</measure>
    <time_frame>Two years</time_frame>
    <description>The accuracy is supported by sensitivity, specificity, negative predictive value and positive predictive value.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>DNA Methylation</condition>
  <condition>Benign Ovarian Tumor</condition>
  <condition>Training Set</condition>
  <condition>Validation Set</condition>
  <condition>Cell-free DNA</condition>
  <condition>Liquid Biopsy</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>DNA methylation testing</intervention_name>
    <description>Methylation testing of host DNA, namely, OPCML, FODX3 and CDH13, in the peripheral serum</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  With definite histological diagnosis of epithelial ovarian cancer and paired benign&#xD;
             ovarian tumor in training set, and with definite histological diagnosis of ovarian&#xD;
             tumor in validation set.&#xD;
&#xD;
          -  With sufficient fresh peripheral serum and ovarian samples for DNA methylation testing&#xD;
             before with or without after major surgeries.&#xD;
&#xD;
          -  Aged 18 years or older.&#xD;
&#xD;
          -  Signed an approved informed consents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not meeting all of the inclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Li, M.D.</last_name>
    <phone>+8613911988831</phone>
    <email>lileigh@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ming Wu, M.D.</last_name>
    <phone>+8613801224549</phone>
    <email>wuming@pumch.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Li, MD</last_name>
      <phone>8613911988831</phone>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>November 26, 2020</last_update_submitted>
  <last_update_submitted_qc>November 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lei Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

